Siglec-15: A potential regulator of osteoporosis, cancer, and infectious diseases

46Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Siglec-15 is a member of the Siglec family of glycan-recognition proteins, primarily expressed on a subset of myeloid cells. Siglec-15 has been known to be involved in osteoclast differentiation, and is considered to be a potential therapeutic target for osteoporosis. Recent studies revealed unexpected roles of Siglec-15 in microbial infection and the cancer microenvironment, expanding the potential pathophysiological roles of Siglec-15. Chemical biology has advanced our understanding of the nature of Siglec-15 ligands, but the exact nature of Siglec-15 ligand depends on the biological context, leaving plenty of room for further exploration.

Cite

CITATION STYLE

APA

Angata, T. (2020, January 3). Siglec-15: A potential regulator of osteoporosis, cancer, and infectious diseases. Journal of Biomedical Science. BioMed Central. https://doi.org/10.1186/s12929-019-0610-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free